Grastek

Grastek is a sublingual immunotherapy (SLIT) tablet used for the treatment of allergic rhinitis caused by grass pollen. It is specifically designed to target allergies to Timothy grass (Phleum pratense) and is approved for use in both children and adults. Grastek is manufactured by ALK-Abelló and marketed in the United States by Merck & Co. under a partnership agreement.

Mechanism of Action

Grastek works by exposing the immune system to small, controlled doses of grass pollen allergens. This exposure helps to build up a tolerance to the allergens over time, reducing the severity of allergic reactions. The tablet is placed under the tongue, where it dissolves and is absorbed into the bloodstream, initiating an immune response.

Indications

Grastek is indicated for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is suitable for patients aged 5 through 65 years who have been diagnosed with a grass pollen allergy confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies.

Administration

Grastek is administered once daily. Treatment should begin at least 12 weeks before the expected onset of the grass pollen season and continue throughout the season. The first dose should be taken under the supervision of a healthcare professional to monitor for any adverse reactions.

Side Effects

Common side effects of Grastek include:

• Oral pruritus
• Throat irritation
• Ear pruritus
• Mouth edema

Severe allergic reactions, including anaphylaxis, are rare but possible. Patients are advised to carry an epinephrine auto-injector in case of severe reactions.

Contraindications

Grastek is contraindicated in patients with:

• Severe, uncontrolled asthma
• A history of severe systemic allergic reactions
• Hypersensitivity to any of the inactive ingredients in the tablet

Related Pages

• Allergic rhinitis
• Sublingual immunotherapy
• Timothy grass
• ALK-Abelló
• Merck & Co.

See Also

• Allergen immunotherapy
• Allergy
• Pollen